Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
With over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications.
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
With deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
Get a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Recombinant monoclonal antibody to CCR4. Mogamulizumab (USAN; trade name Poteligeo) is a humanized monoclonal antibody targeting CC chemokine receptor 4 (CCR4). It has been approved in Japan for the treatment of relapsed or refractory adult T-cell leukemia/lymphoma.
Target
CCR4
Type
IgG1 - kappa
Immunogen
KLH conjugate CCR4 partial peptide
Species Reactivity
Human
Expression Host
CHO
Applications
Suitable for use in Neut, ELISA, IF, IP, FuncS, FC, ICC and most other immunological methods.
CAS
1159266-37-1
Specific Activity
Tested positive against native human antigen.
Protein Construction
Immunoglobulin G1, anti-(human C-C chemokine receptor type 4); humanized mouse monoclonal KW-0761 γ1 heavy chain (222-219")-disulfide with humanized mouse monoclonal KW-0761 kappa light chain, dimer (228-228"":231-231"")- bisdisulfide
Predicted N terminal
H chain: EVQLVES; L chain: DIVMTQS
Molecular Weight
146440
Purity
>95.0% as determined by analysis by SDS-PAGE.
Size
1mg
Storage
Store the antibody (in aliquots) at -20°C. Avoid repeated freezing and thawing of samples.
BACKGROUND
Antigen Description
High affinity receptor for the C-C type chemokines CCL17/TARC and CCL22/MDC. The activity of this receptor is mediated by G(i) proteins which activate a phosphatidylinositol-calcium second messenger system. Can function as a chemoattractant homing receptor on circulating memory lymphocytes and as a coreceptor for some primary HIV-2 isolates. In the CNS, could mediate hippocampal-neuron survival.